Inhibikase Therapeutics Inc. Company Profile
NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
1.94-0.04 (-2.02%)
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 1.94 0.00%
Inhibikase Therapeutics at a glance
Inhibikase Therapeutics Inc. (NASDAQ: IKT) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector. The company's shares have traded publicly since 2020. At a market capitalization of $276.3 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001750149, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
Company information
- Legal name
- Inhibikase Therapeutics Inc.
- Ticker
- NASDAQ: IKT
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Headquarters
- United States
- IPO year
- 2020
- Market cap
- $276.28M
- SEC CIK
- 0001750149
Companies similar to Inhibikase Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XFORX4 Pharmaceuticals Inc. | 2.81 | +1.44% | $278.60M | vs IKT |
| LXEOLexeo Therapeutics Inc. | 3.31 | +0.30% | $271.71M | vs IKT |
| SABSSAB Biotherapeutics Inc. | 2.88 | -1.71% | $262.04M | vs IKT |
| PALIPalisade Bio Inc. | 1.48 | -0.67% | $257.92M | vs IKT |
| FATEFate Therapeutics Inc. | 2.15 | -6.11% | $257.61M | vs IKT |
| SRZNSurrozen Inc. | 25.15 | -4.65% | $295.54M | vs IKT |
| STROSutro Biopharma Inc. | 14.66 | +1.45% | $243.08M | vs IKT |
| LCTXLineage Cell Therapeutics Inc. | 0.9476 | +1.03% | $239.66M | vs IKT |